Precision Oncology’s Messerschmidt Discusses Cancer Vaccine Development in Biocompare


Chief Medical Officer Gerry Messerschmidt authors a new commentary in Biocompare outlining critical success factors toward cancer vaccine development. Messerschmidt counters some high-profile vaccine failures with recent advances that, in fact, have taken us much closer to achieving an effective therapeutic cancer vaccine than ever before.

To read Dr. Messerschmidt’s complete commentary, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.